Prognostic significance of POLE proofreading mutations in endometrial cancer.

ABSTRACT:

Background

Current risk stratification in endometrial cancer (EC) results in frequent over- and underuse of adjuvant therapy, and may be improved by novel biomarkers. We examined whether POLE proofreading mutations, recently reported in about 7% of ECs, predict prognosis.

Methods

We performed targeted POLE sequencing in ECs from the PORTEC-1 and -2 trials (n = 788), and analyzed clinical outcome according to POLE status. We combined these results with those from three additional series (n = 628) by meta-analysis to generate multivariable-adjusted, pooled hazard ratios (HRs) for recurrence-free survival (RFS) and cancer-specific survival (CSS) of POLE-mutant ECs. All statistical tests were two-sided.

Results

POLE mutations were detected in 48 of 788 (6.1%) ECs from POR

SUBMITTER: Church DN 

PROVIDER: S-EPMC4301706 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature